公开(公告)号：EP4433105A1

公开(公告)日：2024-09-25

申请号：EP22818271.3

申请日：2022-11-15

申请人： Glycolink AB

发明人： MCKEE, Lauren ,  HAO, Mengshu ,  ZHOU, Qi ,  KOSKELA, Salla

IPC分类号： A61L26/00

CPC分类号： A61K47/42 ,  C07K14/00 ,  A61L27/52 ,  A61L27/227 ,  A61K9/06 ,  C07K2319/2120130101 ,  C07K14/195

公开(公告)号：EP4428537A2

公开(公告)日：2024-09-11

申请号：EP24169254.0

申请日：2017-04-14

申请人： MARS INCORPORATED

发明人： MCGRANE, Scott, Joseph ,  GIBBS, Matthew, Ronald ,  FINE, Richard, Masten ,  KLEBANSKY, Boris

IPC分类号： G01N33/74

CPC分类号： C07K14/705 ,  C07K14/00 ,  G01N2333/72620130101 ,  G01N2500/0420130101 ,  G01N33/74

摘要： The present disclosure provides methods for identifying compounds that modulate the activity and/or expression of GPR92, wherein said compounds can be incorporated into flavor compositions that can be used to modify the taste and/or palatability of pet food products. In certain non-limiting embodiments, the present disclosure provides a method for identifying a composition that modulates the activity of a GPR92 receptor comprising (a) contacting a test agent with a GPR92 receptor, (b) determining the activity of the GPR92 receptor, and (c) selecting as the composition, a test agent that increases the activity of the GPR92 receptor.

公开(公告)号：EP4424701A1

公开(公告)日：2024-09-04

申请号：EP22897679.1

申请日：2022-11-16

申请人： Suzhou Healirna Biotechnology Co., Ltd.

发明人： ZHAO, Lixiang ,  LU, Qingqing ,  FAN, Yawen ,  YI, Cheng ,  GE, Youzhen ,  XIA, Dan ,  HU, Hongpeng

IPC分类号： C07K7/64 ,  C07K11/02 ,  C07K14/00 ,  A61K38/12 ,  A61K38/16 ,  A61P1/00 ,  A61P5/00 ,  A61P9/00 ,  A61P11/00 ,  A61P19/00 ,  A61P25/00 ,  A61P27/02 ,  A61P27/16 ,  A61P31/04 ,  A61P31/12 ,  A61P37/04

CPC分类号： A61K38/12 ,  A61K38/16 ,  A61K39/00 ,  A61K47/42 ,  A61K47/64 ,  A61K48/00 ,  A61P1/00 ,  A61P5/00 ,  A61P11/00 ,  A61P9/00 ,  A61P19/00 ,  A61P25/00 ,  A61P27/16 ,  A61P31/04 ,  A61P31/12 ,  A61P27/02 ,  A61P37/04 ,  C07K7/00 ,  C07K7/64 ,  C07K7/08 ,  C07K14/00 ,  C07K11/02

摘要： The present invention relates to a novel cyclic peptide carrier in the field of pharmaceutical technology and its various forms, where the cyclic peptide has the general sequence formula P-(X)m-Cys-(Y)n-Cys-(Z)o-P. The invention also encompasses the construction and preparation technology of a composition or formulation formed by the novel cyclic peptide carrier carrying nucleic acids, drugs, or therapeutic agents. Furthermore, it involves a method for effectively delivering nucleic acids to cells, tissues, or organisms using the composition or formulation, as well as its medical applications.

公开(公告)号：EP4417618A1

公开(公告)日：2024-08-21

申请号：EP22880418.3

申请日：2022-10-14

申请人： Xizang Haisco Pharmaceutical Co., Ltd.

发明人： LI, Yao ,  CHEN, Lei ,  HUANG, Haitao ,  WANG, Haodong ,  TANG, Pingming ,  YU, Yan ,  ZHANG, Chen ,  YAN, Pangke

IPC分类号： C07K7/08 ,  A61P35/00 ,  A61K47/64 ,  C07K14/00

CPC分类号： C07K14/00 ,  A61K47/64 ,  C07K7/08 ,  A61P35/00

摘要： Disclosed are a bicyclic peptide ligand having high affinity for Eph receptor tyrosine kinase A2 (EphA2), a drug conjugate containing the bicyclic peptide ligand and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same, and the use of the drug conjugate and the pharmaceutical composition in the preparation of a drug for preventing and/or treating EphA2 overexpressed disease.

公开(公告)号：EP4379054A1

公开(公告)日：2024-06-05

申请号：EP22849476.1

申请日：2022-07-26

申请人： Stand Therapeutics Co., Ltd.

发明人： KABAYAMA, Hiroyuki

IPC分类号： C12N15/12 ,  C07K7/00 ,  C07K14/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/13 ,  C12N15/62 ,  C12N15/63

CPC分类号： C07K14/00 ,  C07K16/00 ,  C12N15/80 ,  C12N15/81 ,  C07K14/435 ,  C07K7/00 ,  C12N15/62 ,  C12N15/63 ,  C12N15/74 ,  C12N5/10

摘要： The present disclosure provides a peptide tag, and a nucleic acid encoding the peptide tag. The peptide tag of the present disclosure can reduce an aggregation property of a protein in a cell. Specifically, the peptide tag of the present disclosure can be a peptide tag in which 5% or more and less than 45% of amino acids contained in an amino acid sequence thereof are acidic amino acids, and (b) 20% or more of the amino acids contained in the amino acid sequence are amino acids selected from the group consisting of F, P, Y, G, S, Q, N, and A.

公开(公告)号：EP4378480A1

公开(公告)日：2024-06-05

申请号：EP22849399.5

申请日：2022-07-22

申请人： Purotech Bio, Inc.

发明人： YANAGAWA, Hiroshi ,  TABATA, Noriko ,  YONEMURA, Yuko ,  IDE, Mayuko ,  ITO, Satoru ,  KANEKO, Shuichi ,  HONDA, Masao ,  SHIRASAKI, Takayoshi ,  MURAI, Kazuhisa ,  OKADA, Hikari

IPC分类号： A61K45/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/16 ,  A61P31/20 ,  C07K7/04 ,  C07K14/00 ,  C12N15/11

CPC分类号： A61K38/10 ,  A61K38/16 ,  A61K38/08 ,  A61K45/00 ,  A61P31/20 ,  C07K7/04 ,  C07K14/00 ,  C12N15/11

摘要： An anti-HBV agent according to the present invention contains as an active ingredient a substance that binds to LIPG and inhibits the function(s) of LIPG. The inventors of the present application have found that LIPG is a factor playing an important role in HBV attachment and uptake, and functions as a cofactor that supports HBV entry into cells independently of NTCP, and also contributes to HBV proliferation in cells. T The LIPG-binding substance binds to LIPG on the surface of liver cells to inhibit HBV attachment and uptake into cells and, when delivered into liver cells, binds to intracellular LIPG to block any step(s) in the intracellular HBV proliferation process, thereby exerting an anti-HBV activity.

公开(公告)号：EP3347034B1

公开(公告)日：2024-05-29

申请号：EP16845118.5

申请日：2016-09-09

IPC分类号： A61K38/16 ,  A61K38/18 ,  C07K14/00 ,  A61P27/02

CPC分类号： C07K14/00 ,  C07K14/4753 ,  A61K38/1833 ,  A61P27/02

公开(公告)号：EP4368631A1

公开(公告)日：2024-05-15

申请号：EP22837695.0

申请日：2022-07-06

申请人： National University Corporation Tokyo Medical and Dental University ,  Cespia Inc.

发明人： FUJIYOSHI, Yoshinori ,  NAKAMURA, Shun ,  NOMURA, Risa ,  TANIMURA, Yukihiro ,  KAMEGAWA, Akiko ,  NUMOTO, Nobutaka

IPC分类号： C07K14/00 ,  A61K9/08 ,  A61K38/10 ,  A61K38/16 ,  A61P31/14 ,  C07K7/08 ,  C12N7/06

CPC分类号： A61K9/08 ,  A61K38/10 ,  A61K38/16 ,  A61P31/14 ,  C07K7/08 ,  C07K14/00 ,  C12N7/06

摘要： Provided is a peptide capable of binding to a receptor binding domain (RBD) in SARS-CoV-2, chemically synthesized easily, having extremely high solubility to ultra-pure water or a buffer solution and a high possibility of being put to practical use as a therapeutic drug for COVID-19.

公开(公告)号：EP3530674B1

公开(公告)日：2024-04-24

申请号：EP17861867.4

申请日：2017-10-19

IPC分类号： C07K19/00 ,  A61K39/125 ,  A61P31/12 ,  C07K7/08 ,  C07K14/00 ,  C07K14/005 ,  C07K14/08 ,  C12N15/09 ,  C12P21/02 ,  C07K16/10

CPC分类号： A61K39/125 ,  A61P31/12 ,  C07K7/08 ,  C07K14/00 ,  C07K14/005 ,  C07K14/08 ,  C07K19/00 ,  C12N15/09 ,  C12P21/02 ,  C07K16/10 ,  C07K2319/1020130101 ,  C07K2319/4020130101 ,  C07K2319/6020130101

公开(公告)号：EP3411407A1

公开(公告)日：2018-12-12

申请号：EP17705564.7

申请日：2017-02-06

申请人： Orionis Biosciences NV ,  VIB VZW ,  Universiteit Gent

发明人： KLEY, Nikolai ,  TAVERNIER, Jan ,  VAN LINT, Sandra ,  CAUWELS, Anje

IPC分类号： C07K16/28

CPC分类号： C07K16/2851 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/57 ,  C07K14/00 ,  C07K14/7156 ,  C07K16/00 ,  C07K16/249 ,  C07K16/2815 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/66 ,  C07K2317/90 ,  C07K2319/00 ,  Y02A50/412

摘要： The present invention relates, in part, to agents that bind Clec9Aand their use as diagnostic and therapeutic agents.The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.